138 related articles for article (PubMed ID: 20887225)
21. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
Fan B; Cen S; Jiang JD
Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
[TBL] [Abstract][Full Text] [Related]
22. Mind the gap: lack of association between KIR3DL1*004/HLA‐Bw4-induced natural killer cell function and protection from HIV infection.
Parsons MS; Boulet S; Song R; Bruneau J; Shoukry NH; Routy JP; Tsoukas CM; Bernard NF
J Infect Dis; 2010 Nov; 202 Suppl 3():S356-60. PubMed ID: 20887224
[TBL] [Abstract][Full Text] [Related]
23. Elite control of HIV infection: implications for vaccine design.
Baker BM; Block BL; Rothchild AC; Walker BD
Expert Opin Biol Ther; 2009 Jan; 9(1):55-69. PubMed ID: 19063693
[TBL] [Abstract][Full Text] [Related]
24. Gram-positive bacteria enhance HIV-1 susceptibility in Langerhans cells, but not in dendritic cells, via Toll-like receptor activation.
Ogawa Y; Kawamura T; Kimura T; Ito M; Blauvelt A; Shimada S
Blood; 2009 May; 113(21):5157-66. PubMed ID: 19279330
[TBL] [Abstract][Full Text] [Related]
25. [Factors involved in resistance to human immunodeficiency virus infection].
Restrepo C; Rallón NI; Benito JM
Med Clin (Barc); 2011 Nov; 137(13):600-4. PubMed ID: 21382628
[TBL] [Abstract][Full Text] [Related]
26. Mucosal innate immunity as a determinant of HIV susceptibility.
Iqbal SM; Kaul R
Am J Reprod Immunol; 2008 Jan; 59(1):44-54. PubMed ID: 18154595
[TBL] [Abstract][Full Text] [Related]
27. Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F.
Ulenga NK; Sarr AD; Thakore-Meloni S; Sankalé JL; Eisen G; Kanki PJ
J Infect Dis; 2008 Aug; 198(4):486-92. PubMed ID: 18598197
[TBL] [Abstract][Full Text] [Related]
28. Natural resistance to HIV infection: lessons learned from HIV‐exposed uninfected individuals.
Pancino G; Saez-Cirion A; Scott-Algara D; Paul P
J Infect Dis; 2010 Nov; 202 Suppl 3():S345-50. PubMed ID: 20887222
[TBL] [Abstract][Full Text] [Related]
29. Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial.
Ripa M; Pogliaghi M; Chiappetta S; Galli L; Pensieroso S; Cavarelli M; Scarlatti G; De Biasi S; Cossarizza A; De Battista D; Malnati M; Lazzarin A; Nozza S; Tambussi G
Clin Microbiol Infect; 2015 Sep; 21(9):876.e1-4. PubMed ID: 25980351
[TBL] [Abstract][Full Text] [Related]
30. Host genetic polymorphisms associated with innate immune factors and HIV-1.
Sobieszczyk ME; Lingappa JR; McElrath MJ
Curr Opin HIV AIDS; 2011 Sep; 6(5):427-34. PubMed ID: 21734565
[TBL] [Abstract][Full Text] [Related]
31. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements.
Chiu YL; Greene WC
Annu Rev Immunol; 2008; 26():317-53. PubMed ID: 18304004
[TBL] [Abstract][Full Text] [Related]
32. The innate immune system and HIV pathogenesis.
Eger KA; Unutmaz D
Curr HIV/AIDS Rep; 2005 Feb; 2(1):10-5. PubMed ID: 16091243
[TBL] [Abstract][Full Text] [Related]
33. APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count.
Cho SJ; Drechsler H; Burke RC; Arens MQ; Powderly W; Davidson NO
J Virol; 2006 Feb; 80(4):2069-72. PubMed ID: 16439564
[TBL] [Abstract][Full Text] [Related]
34. NK cells in HIV infection: paradigm for protection or targets for ambush.
Fauci AS; Mavilio D; Kottilil S
Nat Rev Immunol; 2005 Nov; 5(11):835-43. PubMed ID: 16239902
[TBL] [Abstract][Full Text] [Related]
35. Innate immune activation in primary HIV-1 infection.
Chang JJ; Altfeld M
J Infect Dis; 2010 Oct; 202 Suppl 2(Suppl 2):S297-301. PubMed ID: 20846036
[TBL] [Abstract][Full Text] [Related]
36. The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system.
Argyris EG; Acheampong E; Wang F; Huang J; Chen K; Mukhtar M; Zhang H
Virology; 2007 Oct; 367(2):440-51. PubMed ID: 17631933
[TBL] [Abstract][Full Text] [Related]
37. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.
Kaiser SM; Emerman M
J Virol; 2006 Jan; 80(2):875-82. PubMed ID: 16378989
[TBL] [Abstract][Full Text] [Related]
38. [Soluble factors with inhibitory activity against type 1 Human Immunodeficiency Virus].
Zapata W; Montoya CJ; Rugeles MT
Biomedica; 2006 Sep; 26(3):451-66. PubMed ID: 17176009
[TBL] [Abstract][Full Text] [Related]
39. Innate molecular and anatomic mucosal barriers against HIV infection in the genital tract of HIV‐exposed seronegative individuals.
Broliden K
J Infect Dis; 2010 Nov; 202 Suppl 3():S351-5. PubMed ID: 20887223
[TBL] [Abstract][Full Text] [Related]
40. Cross-talk between virus and host innate immunity in pediatric HIV-1 infection and disease progression.
Freguja R; Gianesin K; Zanchetta M; De Rossi A
New Microbiol; 2012 Jul; 35(3):249-57. PubMed ID: 22842595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
